Log in to save to my catalogue

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive no...

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive no...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2aee772d175142968edb2117d86331be

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

About this item

Full title

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-02, Vol.15 (1), p.1823-1823, Article 1823

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor (
EGFR)
T790M mutation (
n
 = 47) by modulating selective pressure on resista...

Alternative Titles

Full title

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2aee772d175142968edb2117d86331be

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2aee772d175142968edb2117d86331be

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-46008-1

How to access this item